胸腺肽联合比阿培南治疗革兰阴性杆菌重症下呼吸道感染疗效观察

目的 探讨胸腺肽联合比阿培南治疗革兰阴性杆菌重症下呼吸道感染的疗效和安全性.方法 将54例革兰阴性杆菌重症下呼吸道感染患者随机分为胸腺肽联合比阿培南治疗组26例(A组)和比阿培南治疗组28例(B组),疗程均为7～14d.比较两组临床疗效、比阿培南使用时间、细菌清除率及不良反应情况.结果 A、B两组的临床有效率分别为84.6％、82.1％,差异无统计学意义(P＞0.05)；A组治疗时间(8.2±3.4)d,优于B组的(13.2±3.6)d(P＜0.05)；A、B两组细菌清除率86.7％、80.7％ (P ＞0.05).结论 胸腺肽联合比阿培南治疗革兰阴性杆菌重症下呼吸道感染比阿培南单用治疗时间短,且安全,有效,值得临床推广.

Clinical observation of the effect of thymosin combined with biapenem in the treatment of severe lower respiratory tract infection of gram negative bacilli

Objective To evaluate the effect and safety of thymosin combined with biapenem in the treatment of severe lower respiratory tract infection of gram negative bacilli.Methods 54 patients with severe lower respiratory tract infection of gram negative bacilli were randomly divided into study group（group A） and control group（group B）,group A was treated with thymosin and biapenem,group B biapenem.All patients were treated for 7-14 days in a course.The clinical effect,treatment time of biapenem,the bacterial clearance rate and adverse drug reaction betweeen two groups were compared.Results The clinical effective rate of group A and B were 84.6% and 82.1%,respectively,there was no statistical difference（P〉0.05）.Treatment time of biapenem in group A and B was （8.2±3.4） days and （13.2±3.6） days,respectively,there was statistical difference （P〈0.05）.The bacterial clearance rate of group A and B were 86.7% and 80.7%,respectively,there was no statistical difference between two groups（P〉0.05）.Conclusion The treatment time of thymosin combined with biapenem treatment of gram-negative bacilli severe respiratory tract infection was shorter than that of biapenem alone treatment,and it was safe,effective,and worthy of clinical application.